TrialArthritis & rheumatology (Hoboken, N.J.)2017

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

Megan E B Clowse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.